Cargando…

Antiviral Chemotherapyand Prophylaxis of Viral Respiratory Disease

Several antiviral agents are currently available for the treatment and prophylaxis of viral respiratory disease. These include oral amantadine for influenza A and aerosolized ribavirin for respiratory syncytial virus infections. Additional agents, such as rimantadine and intranasal interferons, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sperber, Steven J., Hayden, Frederick G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 1987
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131954/
https://www.ncbi.nlm.nih.gov/pubmed/2446820
http://dx.doi.org/10.1016/S0272-2712(18)30721-2
_version_ 1783517351301349376
author Sperber, Steven J.
Hayden, Frederick G.
author_facet Sperber, Steven J.
Hayden, Frederick G.
author_sort Sperber, Steven J.
collection PubMed
description Several antiviral agents are currently available for the treatment and prophylaxis of viral respiratory disease. These include oral amantadine for influenza A and aerosolized ribavirin for respiratory syncytial virus infections. Additional agents, such as rimantadine and intranasal interferons, and newer approaches, including thе use of combination chemotherapy, offer promise for the improved management of viral respiratory tract infections.
format Online
Article
Text
id pubmed-7131954
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71319542020-04-08 Antiviral Chemotherapyand Prophylaxis of Viral Respiratory Disease Sperber, Steven J. Hayden, Frederick G. Clin Lab Med Article Several antiviral agents are currently available for the treatment and prophylaxis of viral respiratory disease. These include oral amantadine for influenza A and aerosolized ribavirin for respiratory syncytial virus infections. Additional agents, such as rimantadine and intranasal interferons, and newer approaches, including thе use of combination chemotherapy, offer promise for the improved management of viral respiratory tract infections. Elsevier Inc. 1987-12 2018-07-30 /pmc/articles/PMC7131954/ /pubmed/2446820 http://dx.doi.org/10.1016/S0272-2712(18)30721-2 Text en Copyright © 1987 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sperber, Steven J.
Hayden, Frederick G.
Antiviral Chemotherapyand Prophylaxis of Viral Respiratory Disease
title Antiviral Chemotherapyand Prophylaxis of Viral Respiratory Disease
title_full Antiviral Chemotherapyand Prophylaxis of Viral Respiratory Disease
title_fullStr Antiviral Chemotherapyand Prophylaxis of Viral Respiratory Disease
title_full_unstemmed Antiviral Chemotherapyand Prophylaxis of Viral Respiratory Disease
title_short Antiviral Chemotherapyand Prophylaxis of Viral Respiratory Disease
title_sort antiviral chemotherapyand prophylaxis of viral respiratory disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131954/
https://www.ncbi.nlm.nih.gov/pubmed/2446820
http://dx.doi.org/10.1016/S0272-2712(18)30721-2
work_keys_str_mv AT sperberstevenj antiviralchemotherapyandprophylaxisofviralrespiratorydisease
AT haydenfrederickg antiviralchemotherapyandprophylaxisofviralrespiratorydisease